ARS Pharmaceuticals, Inc.
SPRY
$13.77
-$0.87-5.94%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 4,900.00% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 4,900.00% | -- | -- |
| Cost of Revenue | 14.34% | 51.07% | -5.72% | -20.43% | -6.84% |
| Gross Profit | 2,529.17% | 17.82% | 12.53% | 20.18% | 6.84% |
| SG&A Expenses | 420.26% | 28.75% | -32.53% | -34.39% | -36.44% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 285.14% | 32.47% | -23.16% | -29.58% | -28.92% |
| Operating Income | 561.54% | -20.97% | 25.54% | 29.50% | 28.92% |
| Income Before Tax | 800.64% | -28.67% | 27.94% | 31.21% | 50.32% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 796.62% | -28.67% | 27.94% | 31.21% | 50.32% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 796.62% | -28.67% | 27.94% | 31.21% | 50.32% |
| EBIT | 561.54% | -20.97% | 25.54% | 29.50% | 28.92% |
| EBITDA | 562.37% | -20.99% | 25.56% | 29.49% | 28.94% |
| EPS Basic | 787.27% | -26.75% | 29.34% | 32.81% | 64.79% |
| Normalized Basic EPS | 640.48% | -26.75% | 29.37% | 32.76% | 51.87% |
| EPS Diluted | 663.67% | -26.75% | 29.34% | 32.81% | 64.79% |
| Normalized Diluted EPS | 541.52% | -26.75% | 29.37% | 32.76% | 51.87% |
| Average Basic Shares Outstanding | 1.32% | 1.52% | 2.02% | 2.40% | 41.19% |
| Average Diluted Shares Outstanding | 24.01% | 1.52% | 2.02% | 2.40% | 41.19% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |